DREAM-NDDesidustat contre Darbepoétine dans le traitement de l'anémie chez les patients atteints de maladie rénale chronique non dialysés

This clinical trial is all about comparing two treatments for anemia in people who have Chronic Kidney Disease (CKD) but are not on dialysis. The two treatments are Desidustat and Darbepoetin. The main goal is to see which one works better and is safer. This is important because it could help improve care for people with CKD and anemia, a common condition that can make people feel tired and weak due to a lack of healthy red blood cells. During this trial, participants receive either Desidustat or Darbepoetin over a period of up to 30 weeks. The study measures the change in hemoglobin levels, a protein in red blood cells that carries oxygen, from the start to the end of the trial. This helps determine how well each treatment improves anemia. As with any study, there may be potential risks and benefits, which are carefully monitored throughout the trial.